

Overview

Useful For

Interpretation of CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma

Detecting the presence and titer of a specific factor inhibitor directed against coagulation factor VIII

This test is **not useful** for detecting the presence of inhibitors directed against other clotting factors and **will not** detect the presence of lupus anticoagulants.

Method Name

Only orderable as part of a profile. For more information see CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

Medical Interpretation

NY State Available

Yes

Specimen

Specimen Type

Plasma Na Cit

Reject Due To

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Plasma Na Cit	Frozen	14 days	

Clinical & Interpretive

Clinical Information

Factor VIII (FVIII) inhibitors are IgG antibodies directed against coagulation FVIII that typically result in development of potentially life-threatening hemorrhage. These antibodies may be alloimmune: developing in patients with congenital FVIII deficiency (hemophilia A) in response to therapeutic infusions of factor VIII concentrate or autoimmune: occurring in patients without hemophilia (not previously factor VIII deficient) either spontaneously or during pregnancy or in association with autoimmune diseases.

**Reference Values**

Only orderable as part of a profile. For more information see CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

An interpretive report will be provided.

**Interpretation**

The interpretive report will include assay information, background information, and conclusions based on the test results.

**Cautions**

Contamination with excess heparin and hemodilution due to improper specimen collection through an intravenous access device or collection above a running intravenous fluid line may cause spurious results.

**Clinical Reference**

1. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14(2):248-261
2. Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. Semin Thromb Hemost. 2009;35(8):752-759
3. Miller C, Platt S, Rice A, Kelly F, Soucie JM, Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012;10:1055-1061

**Performance****Method Description**

A coagulation expert (clinician or hematopathologist) reviews the laboratory data, and an interpretive report is issued.

**PDF Report**

No

**Day(s) Performed**

Monday through Friday

**Report Available**

3 days

**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

**Fees & Codes**

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

Not Applicable

CPT Code Information

85390-26

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
CH8BI	Chromogenic FVIII Inhibitor Interp	95122-8

Result ID	Test Result Name	Result LOINC® Value
606844	Chromogenic FVIII Inhibitor Interp	95122-8
606865	Reviewed by	18771-6